Thermo Fisher Ion Torrent Genexus Integrated Next-Generation Sequencing System

Overview

The Thermo Fisher Ion Torrent Genexus Integrated Next-Generation Sequencing System represents a paradigm shift in clinical and translational NGS deployment. Engineered for precision, reproducibility, and operational simplicity, the Genexus platform integrates nucleic acid extraction, library preparation, templating, semiconductor-based sequencing, and bioinformatic analysis into a single, unified hardware-software workflow. Unlike conventional NGS platforms requiring discrete instruments and manual handoffs across multiple steps, Genexus leverages Ion Semiconductor Sequencing™ technology—detecting hydrogen ions released during nucleotide incorporation—to deliver real-time, amplification-free sequencing with inherent speed and low error bias in homopolymer regions. Its fully automated architecture reduces hands-on time to under 15 minutes and limits human intervention to only two discrete manual steps: sample loading and run initiation. Designed for routine use in molecular pathology labs, clinical research centers, and core facilities, Genexus meets stringent requirements for traceability, audit readiness, and regulatory compliance without sacrificing analytical rigor.

Key Features

• Fully integrated wet-lab and dry-lab workflow: Combines on-instrument nucleic acid purification, quantification, dilution, library construction, templating, sequencing, QC, variant calling, annotation, and report generation.
• Two-instrument footprint: Genexus Purification System and Genexus Integrated Sequencer operate as a synchronized unit—eliminating inter-device transfer and cross-contamination risk.
• Barcode-driven consumables management: All reagent kits and chips feature embedded RFID and 2D barcodes; software auto-identifies lot numbers, expiration dates, and calibration status.
• Intelligent visual monitoring system: Onboard cameras track liquid handling, chip loading, and reagent dispensing in real time, triggering alerts for deviations or misalignments.
• Four-step intuitive software interface: Guided setup via Genexus Software enables rapid protocol selection, sample assignment, analysis configuration, and report export—no command-line expertise required.
• Scalable throughput: Supports 1–32 samples per run using standardized Ion AmpliSeq™ panels, with seamless transition between low-coverage screening and high-depth targeted sequencing.

Sample Compatibility & Compliance

Genexus accepts diverse clinical and research biospecimens—including formalin-fixed paraffin-embedded (FFPE) tissue, whole blood, plasma, fresh/frozen tissue, and peripheral blood mononuclear cells (PBMCs)—without protocol redesign. The system complies with ISO 13485:2016 for in vitro diagnostic device manufacturing and supports alignment with CLIA, CAP, and IVD Directive (98/79/EC) requirements. For regulated environments, Genexus Software includes full 21 CFR Part 11-compliant audit trails, electronic signatures, role-based access control, and data integrity safeguards. All workflows are validated per manufacturer specifications and align with relevant ASTM E3121 and ISO/IEC 17025 standards for method verification in molecular diagnostics.

Software & Data Management

Genexus Software provides an end-to-end, FDA-cleared (where applicable), HIPAA-compliant informatics environment. It incorporates built-in QC metrics (e.g., % usable reads, duplication rate, coverage uniformity), variant classification per ACMG guidelines, and customizable reporting templates compatible with LIS/HIS integration. Raw signal data (SFF files), BAM/CRAM alignments, VCF outputs, and annotated reports are stored in encrypted, version-controlled repositories with configurable retention policies. The system supports secure cloud backup and local NAS deployment, ensuring continuity of operations and long-term data stewardship in accordance with GLP/GMP documentation practices.

Applications

Genexus is optimized for targeted NGS applications across oncology (somatic mutation profiling, tumor mutational burden, resistance marker detection), infectious disease (pathogen identification, antimicrobial resistance gene screening), reproductive genetics (carrier screening, preimplantation genetic testing), and microbiome research. Its compatibility with Ion AmpliSeq™ Custom Panels enables rapid development of species-agnostic assays—from human germline variants to viral quasispecies or bacterial strain typing—without requiring bespoke bioinformatics infrastructure.

FAQ

What sample types are supported by the Genexus system?

FFPE tissue, whole blood, plasma, fresh/frozen tissue, PBMCs, and other nucleic acid-containing specimens—validated per Thermo Fisher’s application notes.
Is the Genexus platform compliant with 21 CFR Part 11?

Yes—Genexus Software includes electronic signature support, audit trail logging, user authentication, and data integrity controls aligned with FDA expectations.
How does Genexus ensure sequencing accuracy and reproducibility?

Through proprietary ion-sensing chemistry, real-time base calling algorithms trained on >10,000 peer-reviewed studies, and built-in technical replicates within each run.
Can custom panels be developed and deployed on Genexus?

Yes—Ion AmpliSeq Designer enables rapid panel design; custom panels undergo full wet-lab and bioinformatic validation before deployment.
What is the typical turnaround time from sample to report?

As fast as 24 hours for a complete workflow—from nucleic acid extraction to annotated variant report—depending on panel size and depth requirements.